AbbVie, Boehringer Ingelheim, and Lilly have announced limited rebate programs for branded drugs that will experience upcoming WAC price decreases.
AbbVie is offering rebates on certain Linzess NDCs; Lilly products affected are Humalog and Lyumjev; and Boehrinder products include Glyxambi, Jardiance, Synjardy, Synjardy XR, and Trijardy XR.
Click the links below to download detailed PDF information:
Expected WAC Decrease Announcements
McKesson is soon expected to announce WAC Decreases for branded products from AstraZenica and Sanofi.
Decreases are expected to occur January 1, 2026, for certain NDCs of AstraZenica's Farixga and Sanofi's Insulin Glargine U-300.
APCI will pass along more information as it comes from McKesson.